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Objective. New anti-malarial regimens are urgently needed in sub-Saharan Africa because of the increase in drug resistance.
We investigated the safety and efficacy of azithromycin or artesunate combined with sulfadoxine-pyrimethamine used for
treatment of malaria in pregnant women in Blantyre, Malawi. Methods/Findings. This was a randomized open-label clinical
trial, conducted at two rural health centers in Blantyre district, Malawi. A total of 141 pregnant women with uncomplicated
Plasmodium falciparum malaria were recruited and randomly allocated to 3 treatment groups: sulfadoxine-pyrimethamine (SP;
3 tablets, 500 mg sulfadoxine and 25 mg pyrimethamine per tablet); SP plus azithromycin (1 g/day62 days); or SP plus
artesunate (200 mg/day63 days). Women received two doses administered at least 4 weeks apart. Heteroduplex tracking
assays were performed to distinguish recrudescence from new infections. Main outcome measures were incidence of adverse
outcomes, parasite and fever clearance times and recrudescence rates. All treatment regimens were well tolerated. Two
women vomited soon after ingesting azithromycin. The parasite clearance time was significantly faster in the SP-artesunate
group. Recrudescent episodes of malaria were less frequent with SP-azithromycin [Hazard Ratio 0.19 (95% confidence interval
0.06 to 0.63)] and SP-artesunate [Hazard Ratio 0.25 (95% confidence interval 0.10 to 0.65)] compared with SP monotherapy.
With one exception (an abortion in the SP-azithromycin group), all adverse pregnancy outcomes could be attributed to known
infectious or obstetrical causes. Because of the small sample size, the effect on birth outcomes, maternal malaria or maternal
anemia could not be evaluated. Conclusions. Both SP-artesunate and SP-azithromycin appeared to be safe, well tolerated and
efficacious for the treatment of malaria during pregnancy. A larger study is needed to determine their safety and efficacy in
preventing poor birth outcomes. Trial Registration. ClinialTrials.gov NCT00287300
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Added to Sulfadoxine-Pyrimethamine as Treatment for Malaria in Pregnant Women. PLoS ONE 2(11): e1166. doi:10.1371/journal.pone.0001166
INTRODUCTION
More than 30 million women become pregnant in malaria-endemic
areas in Africa each year [1,2]. Infection with Plasmodium falciparum
during pregnancy can cause maternal anemia, abortions, stillbirths,
preterm deliveries and low birth weight [3,4]. In areas of high
transmission, most of the infections in pregnant women are
asymptomatic and consequently, malaria infection may go un-
diagnosed [5]. All pregnant women in these areas should be
provided with intermittent preventive therapy (IPT) at antenatal
visits to prevent infection [6]. Sulfadoxine-pyrimethamine (SP), first
introduced in Malawi in 1993, has now been adopted by many
countries in sub-Saharan Africa as the drug of choice for IPT.
Studies have shown that IPT significantly reduces the prevalence of
placental malaria and low birth weight [7–12].
The increase in the resistance to SP in sub-Saharan Africa is
recognized as a growing public health problem [13]. There are
currently few chemotherapeutic options available for treatment
and prevention of malaria during pregnancy. In addition, limited
data exist on the safety of anti-malarial drugs as pregnant women
have been frequently excluded from most malaria treatment trials
for fear of toxicity to the fetus[14]. Research is urgently needed to
identify alternative anti-malarial drugs that are safe, acceptable
and efficacious in treating and preventing malaria infection in
pregnant women.
The use of combination anti-malarial drugs that target different
pathways is being strongly advocated as a strategy for improving
efficacy and delaying the emergence of drug-resistant parasites
[15]. The combination of conventional anti-malarial drugs with
artemisinin derivatives has been proposed as the next best option
for the treatment of resistant P. falciparum. Artesunate, one of the
artemisinin derivatives, has been used widely in South-East Asia in
non-pregnant individuals. There have been no reports of severe
adverse effects in studies when it was given as treatment in the
second and third trimesters of pregnancy [2,16]. However, due to
the small number of women in these studies, there is still need for
more information on the safety of artesunate in pregnant women.
Additionally, there have been no studies that have assessed the use
of artesunate as IPT in pregnant women.
Azithromycin, a macrolide antibiotic, which has been found to
have anti-malarial effect [17], has been used in pregnant women to
Academic Editor: Piero Olliaro, World Health Organization, Switzerland
Received October 9, 2007; Accepted October 10, 2007; Published November 14,
2007
Copyright:  2007 Kalilani et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This study was funded by CDC grant CDC/ASPH/ASTDR S1935-21/21. Dr
Steve Rogerson is supported by a Wellcome Trust Senior Research Fellowship. The
CDC had no role in the design and conduct of the study, data collection, analysis
and interpretation of the data, in the preparation, review, or approval of the
manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: lkalilani@rsc.medcol.
mw
PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1166treat sexually transmitted infection (STIs), and other infections with
a good safety profile [18,19]. However, there have been no studies
that have investigated its efficacy in treating and preventing malaria
inpregnant women.The objective of this pilot study wasthereforeto
compare the safety and efficacy of SP combined with azithromycin
or artesunate to SP monotherapy (the currently recommended
regimen in Malawi), in treating malaria in pregnant women.
METHODS
Study Participants
The protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1. The study was conducted at Mpemba and Madziabango health
centers in Blantyre District, Malawi from September 2003 to
September 2004. Blantyre district has a population of approxi-
mately 950,000 people [20]. Malaria transmission is perennial, but
peaks during the rainy season (November–March). P. falciparum
causes over 90% of all malaria infections. The two health centers
have maternity beds for delivery of low risk pregnancies. Women
with high risk pregnancies are referred to Queen Elizabeth Central
Hospital (QECH), a tertiary hospital located about 10 km from the
health centers for management.
Women were eligible if they had peripheral parasitemia
(Plasmodium falciparum), were 15–49 years old, the estimated fetal
gestational age was 14–26 weeks, the mother had felt fetal
movements and if they were available for follow-up until delivery.
Women were excluded if they had multiple gestations, a history of
chronic diseases such as tuberculosis and diabetes, a mental
disorder, known allergies to drugs containing sulfonamides,
macrolides or pyrimethamine, pregnancy complications, or if they
had taken anti-malarial drugs within 28 days before enrollment.
Written or witnessed verbal informed consent was obtained prior
to enrollment. This study was approved by the College of
Medicine Research Committee (University of Malawi) and the
Institutional Review Boards of the University of North Carolina
(Chapel Hill, North Carolina).
Study Design
This was an open-label, randomized clinical trial. At enrollment,
a standardized questionnaire was administered to collect de-
mographic information, history of malaria illnesses, and past
medical and obstetric history. The women received routine
antenatal assessment and could choose to be tested for human
immunodeficiency virus (HIV) infection, with pre- and post-test
counseling. A venous blood sample was obtained to measure
hemoglobin concentration and prepare thick blood films.
The women were randomly assigned to one of three treatment
armsandreceived two dosesofthe assignedtreatment.The first dose
was given at enrollment. The second dose was administered at least
4 weeks after the first dose, irrespective of whether or not
parasitemiawasdetected.Thickfilmswereexaminedforparasitemia
on days 1,2,3,7 and 14 after each treatment, and at scheduled and
unscheduled antenatal visits. Body temperature was recorded every
6 hours after treatment until it became normal (,37.5uC). The
women were followed until delivery, and at each subsequent visit
they received routine antenatal care, and information was obtained
on malarial illnesses, use of anti-malarial drugs, and potential side
effects of the study drugs. The women were asked not to self-
administer anti-malarial drugs, but to return to the health centers for
evaluation any time they experienced symptoms of malaria.
All symptoms reported by the women at any time after taking the
study medication were recorded by the study nurses. The study
physician assessed these reported symptoms by conducting further
interviews and physical examination. Treatment was discontinued if
there were serious adverse events, and these were reported to the
institutional review boards of the University of Malawi, College of
Medicine and the University of North Carolina within 48 hours. A
Data Safety Monitoring Committee reviewed adverse event data
midway through the study. Symptoms present at baseline in women
with parasitemia were considered to be attributable to malaria.
Womenwith mildormoderateadverse eventsweremonitoredatthe
health centers with outpatient management as recommended by the
study physician. Women with severe adverse events requiring
hospitalization were monitored at the health centers or referred to
QECH. They were visited daily by the study nurses and/or
physician in order to document progression and resolution of the
symptoms and to provide any clinical assistance deemed necessary.
All HIV-positive women were given nevirapine (Roxane
Laboratories, Columbus, Ohio, USA) at the onset of active labor
according to the HIVNET 012 protocol [21]. Newborns delivered
at the health centers or QECH were examined for the presence of
visible physical congenital abnormalities by trained midwives who
were not blinded to treatment allocation. The newborns were
weighed using a digital scale (to the nearest gram) and gestational
age was estimated using the Ballard score [22] within 24 hours of
delivery. A blood sample was obtained from a maternal peripheral
vein, the placenta and the umbilical cord for preparation of thick
films and estimation of maternal hemoglobin concentration. Full
thickness placental biopsies were collected to prepare histology
slides. If a traditional birth attendant was present during home
deliveries, birth weight was measured using color-coded scales that
indicated red for birth weight less than 2,500g and green for birth
weight at least 2,500 g. Peripheral, placental and cord blood thick
blood films were prepared and forwarded to the health-centers
through community health workers. Newborns delivered at home
were later examined by the trained midwives when the mother
presented at the health centers.
Intervention
The three treatment arms were: (1) SP(3tablets;500 mgsulfadoxine
and 25 mg pyrimethamine per tablet); (2) SP (3 tablets) plus
azithromycin (1 g/day for 2 days) and (3) SP (3 tablets) plus
artesunate (200 mg/day for 3 days). Administration of the drug was
under direct observation. A full dose of the drug was re-administered
if the medication was vomited within 30 minutes of ingestion.
Women stayed at the health center for at least an hour after taking
the drug. Women who lived far away spent 2 nights at the health
center or were visited at home. Women with parasitemia between
days 7 and 28 after taking the assigned treatment were given quinine
(600mg, 3 times/day for 5 days). All drugs were purchased at once
fromthesamebatchandstoredinadrycoolplace.Thewomenwere
alsogiven200mg offerrous sulfate and 0.25 mgof folic acidfor daily
administration, and insecticide treated bed-nets.
Objectives
The primary objective of the trial was to compare the safety of the
combination of SP with azithromycin or artesunate to that of SP
alone, which is the current standard treatment for malaria and
IPT in pregnant women Malawi. The secondary objective, efficacy
was assessed by recrudescence rates, parasite and fever clearance
times, and birth outcomes.
Outcome measures
Adverse events Adverse events were classified as mild if
symptoms were transient or there was mild discomfort requiring
no medical intervention. Moderate adverse events were defined as
Malaria in Pregnant Women
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no or minimal medical therapy. Symptoms were classified as
severe adverse events if they caused marked limitation in activity
and required medical intervention or hospitalization. Life
threatening adverse events caused extreme limitation with
significant medical therapy and hospitalization.
Treatment failure Recurrent episodes detected between days
7 and 14 were classified as recrudescence without genotyping,
because they were assumed very unlikely to be new infections [23].
Forrecurrentepisodesdetected after day 14,we genotyped themsp-1
gene using a Heteroduplex Tracking Assay (HTA) [24–26] to
distinguish between recrudescence and new infections. Genotyped
recurrent episodes were classified as recrudescence if all the variants
or a subset of the alleles (at least one identical uncommon band with
prevalence ,10% or at least 2 common bands with a prevalence
.10%) detected in a recurrent episode, were identical to those
present in the initial infection.
Parasite clearance time In women who had parasitemia,
this was defined as the time (in days) from receiving the assigned
treatment to the time when parasites were not detected in the
peripheral blood.
Fever clearance time This was defined as the time (in hours)
from receiving the assigned treatment to the time a normal body
temperature was recorded (#37.5uC), in women who presented
with fever.
Maternal and birth outcomes Newborns were classified as
having normal ($2,500 g) or low (,2,500 g) birth weight,
regardless of gestational age. Prematurity was defined as delivery
before 37 estimated weeks of gestation. Abortion was defined as
delivery of a non-viable fetus before 28 weeks of gestation.
Stillbirth was defined as delivery of a dead fetus after 28 weeks
of gestation. Neonatal death was defined as death occurring during
the first 27 completed days of life. Women were defined as having
anemia if they had hemoglobin concentration less than 11g/dL.
Sample size
This study was designed as a pilot for a larger randomized clinical
trial. The sample size was chosen based on financial and logistical
restraints.
Randomization: Sequence Generation, Concealment
and Allocation
The women were randomly assigned to the three treatment groups
using a list of random numbers that were grouped in blocks of 4–
10. These random numbers were generated by an independent
statistician who was not involved in conducting the study. Each of
the generated numbers was assigned a treatment group, sealed in
envelopes and forwarded to the local investigator prior to the start
of the study. The randomization list was then secured in a locked
cabinet at the study site, accessible only by the study nurse. Once
a patient met the inclusion criteria and had given consent, she was
assigned the number following the one of the previous patient. The
envelope corresponding to that number was opened by the
research nurse to identify the treatment group. The entire process
was completed before any procedure was started for the following
patient.
Blinding
Neither the study nurses nor the patients were blinded to the
treatment allocation. However, microscopists who examined thick
films for parasitemia were blinded to the treatment allocation.
Additionally, histology and genotyping was performed by
individuals who were blinded to the treatment allocation.
Laboratory procedures
Parasitology Malaria diagnosis was performed by microscopy of
Giemsa stained thick blood films. Parasite density was estimated
using an assumed leukocyte count of 6,000 leukocytes/ml of blood. A
thick film was considered negative if no parasites were detected after
examining 100 microscopic fields each containing approximately 20
leukocytes. All thick films were read by two skilled microscopists.
Discrepancies were resolved by repeating the readings.
Parasite Genotyping An assay using real-time Polymerase
Chain Reaction and sequence-specific probes[27] was used to
detect point mutations in the genes encoding dihydropteroate
synthase (dhps) and dihydrofolate reductase (dhfr), which have been
associated with SP resistance [28].
Histopathology Fixed placental biopsies were wax
embedded, and cut into 4 mm thick sections. Histological slides
were prepared by staining with Gurr’s modified Giemsa and/or
Hematoxylin and Eosin. The slides were examined for presence of
P. falciparum infected erythrocytes and hemozoin deposition in
fibrin or monocytes [29].
Hemotology Hemoglobin concentration was measured using
a HemoCue hemoglobinometer (HemoCue Incorporated,
Angelholm, Sweden).
HIV Testing This was performed using two enzyme immuno-
assays, Determine HIV-1/2 Rapid Test (Abbott Laboratories,
Illinois, USA) and Unigold Test (Trinity Biotech plc, Dublin,
Ireland) according to the manufacturers’ instructions. Discordant
results were resolved using a third assay, Hemastrip Rapid Test
(ChemBio Diagnostic Systems).
Statistical Methods
Data analysis was conducted using STATA version 8 (Stata
Corporation, TX, USA), using the intent-to-treat principle. The
primary end point was the frequency of adverse events in the
women and the newborns. The secondary outcomes included
recrudescence rates, parasite and fever clearance times, the
prevalence of maternal anemia, peripheral and placental para-
sitemia at delivery, and the incidence of low birth weight.
Categorical variables were compared using the Chi-square or
Fisher’s exact test, and continuous variables were compared using
the analysis of variance for normally distributed, and the Kruskal-
Wallis tests for non-normally distributed variables.
The difference in the HTA-adjusted recrudescence rates for the
three treatment groups was determined by survival analysis.
Follow-up time was calculated in days from initial infection to
occurrence of an event (recrudescence), or censoring (delivery or
loss to follow-up). Kaplan-Meier survival curves assessed the
independent predictors of treatment outcome. Comparison of the
survival curves was performed using the Log-rank test. A
conditional risk-set Cox proportional hazards regression model
compared the efficacy of the three treatment regimens [30,31].The
baseline hazard was stratified by the number of treatment doses
received. Only women with new infections were included in the
analysis because they were at risk for recrudescence. A robust
variance estimator was included in the model to account for the
intra-individual correlation [32]. Other covariates included in the
analysis were baseline parasite density, gravidity, HIV status, and
history of receiving quinine during the follow-up period. The
baseline parasite density was log-transformed to obtain a normal
distribution.
RESULTS
A total of 141 pregnant women with uncomplicated P. falciparum
infection were recruited into the study, 47 women in each
Malaria in Pregnant Women
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losses are shown in Figure 1. Twenty-three women were lost to
follow-up. Reasons included permanent movement from the study
area (n=5), withdrawal from the study (n=16), and delivery
outside the study area (n=2). The median follow-up period was
102 days (range 2–178 days). All women received at least one
treatment course of the assigned drug and 121 women received
a second course. The demographic and clinical characteristics of
the women were very similar across the treatment groups (Table 1).
Only 89 (63.1%) women accepted to have an HIV test result, and
of these, 26 (29.2%) were HIV-positive. The proportion of HIV-
infected women was higher in the SP [33.3%, (9/27)] and SP-
azithromycin groups [34.5%, (10/29)] than in the SP-artesunate
group [21.2%, (7/33)]. Of the samples obtained at enrollment,
138 (98%) were genotyped. Mutations were present in 132 (97%)
of the samples at dhfr-59 and 118 (90%) of the samples at dhps-540.
The genotyping results imply a moderate to high level of SP
resistance [33].
Primary Outcomes
1. Maternal adverse events Artesunate and azithromycin
were well tolerated. There were no serious or clinically significant
treatment-associated adverse reactions reported. Early drug-
induced vomiting occurred in 2 women after taking the first
dose of SP-azithromycin. Two other women reported having
general body pains and diarrhea after receiving the first dose of
SP-azithromycin. Three women reported symptoms after
receiving the second dose of SP-azithromycin which included
abdominal pains, general body pains and headache. Of these
women, 2 had no parasitemia at the time they received the second
dose of SP-azithromycin.
In the SP group, 1 woman reported abdominal pains and fever
after receiving the first dose. Six women reported symptoms after
receiving the second dose which included abdominal pains,
general body pains, vomiting, cough, headache, fever and skin
rash. Three of these women had parasitemia at the time they
received the second dose of SP.
In the SP-artesunate group, 6 women reported the following
symptoms after receiving the first dose: general body pains,
abdominal pains, diarrhea, cough, headache, fever and nausea.
Six other women reported symptoms after receiving the second
dose. These symptoms included general body pains, diarrhea,
coughing and headache. Only 1 of these women had parasitemia
at the time they received the second dose of SP-artesunate.
2. Pregnancy outcomes Of the 118 deliveries with known
outcomes, there were 109 live births, 4 spontaneous abortions and
5 still births (Table 2). All 4 abortions occurred in the SP-
azithromycin group. Three of the abortions occurred 25–29 days
after treatment in women who had malaria (1), HIV (1) or malaria
and HIV (1). There was 1 stillbirth in the SP, none in the SP-
azithromycin and 4 in the SP-artesunate group. Two stillbirths
occurred after prolonged labor, 1 occurred after the mother had
taken traditional medicine to induce labor, 1 had the cord around
the neck at delivery, and in 1 stillbirth, the mother had a positive
39 women received the 
second dose of study drug 
47 women received the 
first dose of study drug 
SP
(47 women) 
47 women received the 
first dose of study drug  
47 women received the 
first dose of study drug 
SP-Artesunate
(47 women) 
40 women received the 
second dose of study drug 
38 finished follow-up 
42 women received the 
second dose of study drug
42 finished follow-up 
1 withdrew 
2 delivered 
outside study 
area
3 withdrew 
2 moved out 
of the area
6 withdrew 
2 moved out 
of the area
6 withdrew 
1 moved out 
of the area 
38 finished follow-up 
SP- Azithromycin 
(47 women) 
Total number of women screened = 1468 
Total number of eligible women = 225 
Total number of women who refused enrollment = 84 
Total number of women enrolled = 141 
Figure 1. Flow diagram of the study participants. The total number of women who received the first and second treatment doses and were
followed until delivery.
doi:10.1371/journal.pone.0001166.g001
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group, 1 in the SP-azithromycin and 3 in the SP-artesunate group.
Two of the neonatal deaths occurred 5 to 9 days after delivery, 4
neonatal deaths occurred soon after delivery, secondary to
premature delivery at 29–31weeks and 2 neonatal deaths
occurred a few hours after delivery due to complications of
labor (obstructed labor). Thus, the abortions, still births and
neonatal deaths potentially had other proximal causes.
Clinically diagnosed kernicterus was detected in one infant,
born at 36 weeks gestation, weighing 2150g at delivery, whose
mother was treated with SP. Table 3 contains further details
related to the adverse pregnancy outcomes.
Secondary Outcomes
1. Recrudescence Rates Microscopic re-appearance of P.
falciparum parasites after the first treatment was detected in 33
(27.3%) of the 121 evaluable women. HTA-genotyping indicated
that 21 (70%) of these episodes were recrudescence (Figure 2). The
overall median time to recrudescence was 34 days (range 7–
133 days). The highest recrudescence rate was 35.0% (14/40) in
women who had received SP, compared with 9.5% (4/42)inwomen
given SP-azithromycin, and 7.7% (3/39) for the SP-artesunate
group, p,0.01. Of the 12 new infections identified at the time of
receiving the second treatment [SP (2), SP-azithromycin (3) and SP-
artesunate (7)], 2 resulted in recrudescence (HTA-corrected), both in
Table 1. The baseline characteristics of the pregnant women enrolled into the clinical trial
..................................................................................................................................................
Characteristic Treatment Group
SP Only SP & Azithromycin SP & Artesunate
(n=47) (n=47) (n=47)
Age in years, median (IQR) 20 (18–24) 20 (18–23) 20 (17–24)
Body weight in kg, mean (SD) 53.3 (5.9) 52.2 (6.1) 52.9 (5.9)
Married (%) 44 (93.6) 38 (80.0) 43 (91.5)
Education (%)
None 3 (6.4) 9 (19.2) 8 (17.0)
Primary 42 (89.4) 31 (65.9) 32 (68.1)
Secondary/Tertiary 2 (4.3) 7 (14.9) 7 (14.9)
Gravidity, median [IQR] 1 (1–3) 1 (1–3) 1 (1–3)
Primigravidae (%) 27 (57.5) 25 (53.1) 28 (59.6)
Secundigravidae (%) 5 (10.6) 7 (14.9) 4 (8.5)
Gestation weeks at 1
st consultation, median (IQR) 22 (20–24) 24 (20–24) 22 (20–24)
Parasitemia/ml, geometric mean [range] 964.5 (180–22500) 1184.2 (150–22500) 686.6 (120–4260)
Hemoglobin concentration in g/dL, mean (SD) 10.2 (1.8) 10.0 (1.4) 10.5(1.6)
HIV Positive
{ (%) 9 (33.3) 10 (34.5) 7 (21.2)
{Only 89 women accepted to have an HIV test; SP group (n=27), SP-azithromycin group (n=29), SP-artesunate group (n=33)
doi:10.1371/journal.pone.0001166.t001
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Table 2. Maternal and fetal outcomes according to treatment group
..................................................................................................................................................
Outcome
Treatment Group
SP SP & Azithromycin SP & Artesunate P-value*
Peripheral parasitemia at delivery (%), n=101 10 (30.3) 9 (27.3) 5 (14.3) 0.50, 0.10,
Placental parasitemia by microscopy (%),n=99 5 (16.1) 9 (27.3) 4 (11.4) 0.22, 0.42
Placental parasitemia by histology, n=70 11 (47.8) 9 (50.0) 13 (44.8) 0.57, 0.53
Cord blood parasitemia, n=99 0 2 (4.3) 1 (2.1) 0.26, 0.53
Hemoglobin concentration, g/dL (mean, SD), n=99 12.6 (2.3) 12.6 (2.3) 13.0 (2.0) 0.54, 0.81
Maternal anemia (%) 8 (24.2) 8 (25.8) 5 (14.2) 0.56, 0.23
Perinatal mortality, n=118 5 (13.2) 5 (11.9) 7 (18.4) 0.56, 0.38
Spontaneous abortions (%) 0 4 (8.5) 0 0.07, 1.00
Still birth (%) 1 (2.1) 0 4 (8.5) 0.50, 0.18
Neonatal deaths (%) 4 (8.5) 1 (2.1) 3 (6.4) 0.15, 0.50
Gestational age at delivery, weeks (median, IQR), n=118 38 (29–42) 36 (33–42) 37 (34–42) 0.18, 0.22
Birth weight , grams, (mean, SD), n=114 2868.6 (625.2) 2784.7 (536.6) 2836.2 (482.0) 0.72, 0.86
Low birth weight (%) 8 (22.2) 6 (16.7) 6(17.7) 0.31, 0.38
*- The first p-value compares outcomes in the SP-azithromycin to the SP group. The second p-value compares outcomes in the SP-artesunate to the SP group.
doi:10.1371/journal.pone.0001166.t002
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Overall, recrudescent episodes (PCR-corrected) were significantly
less frequent in the SP-azithromycin [Hazard ratio (HR) 0.23, (95%
confidence interval (CI) 0.08–0.71)] and SP-artesunate treatment
groups [HR 0.25 (95% CI 0.10–0.61)] compared with SP
monotherapy (Figure 3). The combination regimens also provided
slightly more protection from recurrences (PCR-uncorrected) than
SP alone. The incidence rate for recurrences (per 1000 person days)
was 4.4 for the SP group (n=19); 3.0 for the SP-azithromycin
(n=13); and 3.9 for the SP-artesunate group (n=17).
After adjusting for gravidity and baseline parasite density,
recrudescent episodes of malaria were still less frequent in the SP-
azithromycin [HR 0.19 (95% CI 0.06–0.63)] and the SP-
artesunate groups [HR 0.25 (95% CI 0.10–0.65)] than with SP
monotherapy. There was no significant difference in efficacy
between the SP-azithromycin and SP-artesunate groups. Re-
crudescent episodes remained less frequent in the SP-azithromycin
[HR 0.14 (95% CI 0.02 to 0.78)] and the SP-artesunate groups
[HR 0.13 (95% CI 0.03 to 0.53)] after including HIV in the
model. Sensitivity analysis confirmed that there were lower
recrudescence rates in women who received the two combination
therapies compared with those given SP monotherapy, after taking
into account possible misclassification of recrudescence [26].
2. Parasite/Fever clearance times SP-artesunate
significantly accelerated the clearance of parasites compared
with SP-azithromycin or SP, even after adjusting for baseline
parasite density level. By day 2, the parasite clearance rates were
significantly higher for women allocated to SP-artesunate [39/47,
(83.0%)] than those given SP [12/47, (25.5%)] and SP-
azithromycin [11/47, (23.4%)]; p,0.001. By day 3, the parasite
clearance rate for SP-artesunate was [46/47, 97.8%] compared
with [33/47, (70.2%)] and [35/47, (74.5%)] in the SP and SP-
azithromycin groups respectively. None of the women in the SP-
azithromycin and SP-artesunate groups had parasitemia on day 7.
However, 4 (8.5%) women in the SP group still had parasitemia on
day 7 and 2 (4.3%) were parasitaemic on day 14.
There were 8 women who had fever at the time of enrollment
[SP (n=3); SP-azithromycin (n=3); SP-artesunate (n=2)]. None of
the women had fever 3 days after treatment, and none of the
women had fever at the time they received the second dose of the
study drug.
3. Maternal parasitological and hematological responses at
delivery W o m e nw i t hm i s s i n gi n f o r m a t i o no no u t c o m e sh a de i t h e r
delivered at home in the absence of a traditional birth attendant or
outside the study area and therefore samples were not collected. The
prevalence of peripheral parasitemia at deliverywas similar across the
treatment groups (Table 2). There appeared to be more women with
placental malaria diagnosed via microscopy for SP-azithromycin [9,
(27.3%)] than SP [5, (16.1%)] and SP-artesunate [4, (11.4%)] groups.
However, histologically the number of women with placental
parasitemia was very similar across the treatment groups, SP [11,
(47.8%)] vs. SP-azithromycin [9, (50.0%)] vs. SP-artesunate [13,
(44.8%)), p=0.95. The maternal hemoglobin concentration was
higher at delivery than at enrolment for all treatment groups [SP
(12.6 g/dL vs. 10.2 g/dL); SP-azithromycin (12.6 g/dL vs.1 0 . 0g /
dL) and SP-artesunate (13.0 g/dL vs. 10.5 g/dL)], but there was no
significant difference between the groups, p=0.48.
4. Birth weight One hundred and six (89.8%) of the 118
babies were weighed and gestational ages assessed within 24 hours
of delivery. There was no difference in the gestation age between
the groups, and no visible physical abnormalities were detected in
any of the newborn babies. There was also no significant
difference in the mean birth weights of infants born to mothers
in the SP (2,868.6 g, SD 625.2 g), SP-artesunate (2,836.2 g, SD
482.0 g) and the SP-azithromycin (2,784.7 g, SD 536.6 g) groups
(Table 3), probably because of the small sample size.
Table 3. Details related to the adverse pregnancy outcomes
..................................................................................................................................................
Patient
No Treatment Group Outcome Details related to death
Days after
last dose
1 SP Stillbirth Prolonged labor, birth weight 3 kg, unknown HIV status 92 days
2 SP NND after 5 days Birth weight 2150 g, had Kernicterus diagnosed by clinical symptoms, unknown HIV status 78 days
3 SP NND after 9 days NA, HIV positive 142 days
4 SP NND Preterm delivery at 29 weeks, unknown HIV status 33 days
5 SP NND Preterm delivery at 29 weeks, birth weight 930g, MPs+, HIV negative 30 days
6 SP-Artesunate NND Preterm delivery at 28 weeks, HIV positive 29 days
7 SP-Artesunate Stillbirth Full term delivery, weight 2.7 kg, cord around the neck, MPs+, HIV positive 11 days
8 SP-Artesunate NND Preterm delivery at 28 weeks, birth weight 1.3 kg , HIV negative 31 days
9 SP-Artesunate Stillbirth Full term, took traditional medicines to enhance labor, MPs+ , HIV positive 99 days
10 SP-Artesunate Stillbirth Preterm delivery at 31 weeks, birth weight 2 kg, VDRL 1:64 positive and TPHA positive,
unknown HIV status
29 days
11 SP-Artesunate Stillbirth Prolonged labor, birth weight 2600 g, unknown HIV status 127 days
12 SP-Artesunate NND Obstructed labor, birth weight 2600 g, HIV negative 79 days
13 SP-Azithromycin NND Obstructed labor, birth weight 2800 g, MPS+ , no data on HIV status 54 days
14 SP-Azithromycin Abortion at 26 weeks NA, unknown HIV status 4 days
15 SP-Azithromycin Abortion at 25 weeks MPs+, unknown HIV status 25 days
16 SP-Azithromycin Abortion at 27 weeks HIV Positive, MPs+ 28 days
17 SP-Azithromycin Abortion at 27 weeks HIV positive 29 days
SP- Sulfadoxine-Pyrimethamine; NND- neonatal death; MPs-malaria parasites detected in the maternal peripheral or placental blood; NA-no information available related
to the abortion or neonatal death; VDRL-Venereal Disease Research Laboratory test; TPHA- Treponema pallidum hemagglutination assay; HIV-human immunodeficiency
virus
doi:10.1371/journal.pone.0001166.t003
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Our results show that in Malawi, where P. falciparum resistance to SP
has been detected [33,34], SP plus azithromycin or artesunate were
more efficacious in treating malaria in pregnant women than SP
monotherapy.Inaddition,the artesunatecombinationshortened the
clearance time of parasites. Both regimens were well tolerated. No
treatment-related severe adverse events were demonstrated, but
larger studies will be needed to rule out associations with abortions,
still births and neonatal deaths. We could not evaluate the difference
in the birth weight, maternal hemoglobin concentration, peripheral
and placental parasitemiaacross the treatment groups because of the
small sample size in this study.
Recent studies have shown that the combination SP-artesunate
is effective against uncomplicated P. falciparum infection in African
children [35,36]. However, very few studies have investigated the
safety and efficacy of SP-artesunate in treating malaria during
pregnancy. A study conducted in Sudan found that SP-artesunate
was efficacious in treating uncomplicated P. falciparum malaria in
32 pregnant women with no adverse effects [37]. Women who
were exposed to SP-artesunate in the Gambia during mass drug
administration did not experience adverse effects and delivered
babies with higher birth weight compared with women who did
not receive treatment [38]. Other studies have also found that
artesunate alone or in combination with mefloquine, atovaquone,
proguanil or quinine was efficacious and safe in all trimesters of
pregnancy [2,16,39–41]. The rapid elimination of parasites by SP-
artesunate would increase the number of days that pregnant
women are aparasitemic hence reducing the risk for low birth
weight and maternal anemia.
However, SP-azithromycin may have several advantages. First,
although the parasite clearance rate was slow compared with the SP-
artesunate group, the rate of recrudescence was similar to SP-
artesunate. Secondly, there has been concern expressed about the
use of artemisinin derivatives in first trimester based on animal
studies [42]. While there is no evidence for similar adverse events in
human pregnancies [43], it is very difficult to prove safety and there
will be a continued reluctance to use artemisinin containing drugs in
first trimester. In contrast, azithromycin has been used in pregnant
womentotreat STIsand otherinfectionseveninthe first trimesterof
pregnancy with a very good safety profile [18,19,44]. Thirdly, the
use of azithromycin for the prevention of STIs in pregnant women
has been shown to reduce the incidence of low birth weight and
neonatal deaths [18]. In most developing countries where the
prevalence of malaria and STIs is high, resources are limited.
Screening and laboratory confirmation of STI-related symptoms is
usually not feasible. Therefore, using SP-azithromycin to treat
pregnant women with malaria may also protect mothers against
other infectious causes of poor birth outcomes. Fourthly, azithro-
mycin has a relatively long half-life compared with artesunate. The
combination of artesunate and a drug with a long half-life (such as
SP) would leave the longer-acting drug unprotected, increasing the
probability of parasites encountering sub-therapeutic drug levels,
and promoting the development of resistance [45].
Studies have found that pregnant women who are co-infected
with HIV have higher prevalence rates of P. falciparum infection
and higher parasite density levels compared with HIV non-
infected women, indicating that HIV impairs the immune
response against malaria [46]. The optimum approach for IPT
in HIV-infected women still remains unclear. Many women in our
study refused to have an HIV test, limiting our ability to analyze
the effect of HIV on efficacy of the combination therapies because
of the small sample size. However, when we re-analyzed our
primary endpoint in the subgroup of women whose HIV status
was known, and incorporated HIV status into our model, the
Hazard Ratios we derived for treatment failure remained very
similar, suggesting HIV infection was not compromising the
higher efficacy of the two combinations over SP alone.
The two combination regimens were relatively well tolerated.
The minor side-effects reported by the women, were difficult to
distinguish from symptoms of uncomplicated malaria. There was
121 women no treatment failure  21 Treatment failures 
141 Episodes of parasitemia at 
enrollment treated with the 1
st dose of 
the assigned drug 
14 SP 
4 SP-azithromycin 
3 SP-artesunate 
12 New infections at the 
time women received the 
2
nd treatment dose
2 Treatment failures 
    (SP-artesunate) 
Figure 2. Recrudescence rates according to the number of treatment doses. The recrudescence rates in the three treatment groups after receiving
each treatment.
doi:10.1371/journal.pone.0001166.g002
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groups. Although spontaneous abortions only occurred in the SP-
azithromycin group, three of the four abortions occurred long
after drug ingestion in women with HIV and/or malaria
infections. This single unexplained abortion could have been
a chance occurrence. A previous study reported 6 abortions out of
the 123 women who were exposed to azithromycin during
pregnancy [19]. Therefore, this outcome needs to be closely
monitored in future studies that use azithromycin to rule out an
association. Three still births occurred in the SP-artesunate group,
but, again, a long time had elapsed between the time of drug
administration and the occurrence of the still births. The short
half-life of artesunate would suggest that it was unlikely these still
births were associated with the treatment. Additionally, other
obstetric explanations could be found for all 3 still births.
Malawi introduced SP as first-line treatment for uncomplicated P.
falciparum infection and for IPT in 1993. The prevalence of clinical
failure and drug resistance mutations in parasite enzymes associated
with resistance to SPhave risen in recent years [34,47], but currently
SP is still effective as IPT [48]. While SP may eventually become
obsolete, combinations of SP and either artesunate or azithromycin
may provide a more effective alternative to SP IPT until new agents
can be developed. Choosing the optimal drug combination will
depend on many factors such as transmission dynamics, cost, safety,
dosing requirements and acceptability. There is also a need to
consider interactions with anti-retroviral drugs in areas where the
HIV prevalence is high, as is the case for Malawi [49].
In conclusion, this pilot trial found that SP combined with
azithromycin or artesunate was efficacious in treating and
preventing malaria in pregnant women. These preliminary results
are promising and should encourage further and larger treatment
studies to confirm the efficacy and safety of the combination of SP
with artesunate or azithromycin in pregnant women. This
information will be very important for the formulation of anti-
malarial drug policy.
SUPPORTING INFORMATION
Checklist S1 CONSORT checklist
Found at: doi:10.1371/journal.pone.0001166.s001 (0.05 MB
DOC)
Protocol S1 Trial protocol
Found at: doi:10.1371/journal.pone.0001166.s002 (0.16 MB
DOC)
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Follow-up time (days)
0
.
0
0
0
.
2
5
0
.
5
0
0
.
7
5
1
.
0
0
0 10 20 30 40 50
-
Number at risk: 
SP            49          43         37      19                    5 
SP-azithromycin     50                      48         44      20        16 
SP-artesunate         54          49         44      23          7 
SP SP-azit
SP-artesunate
SP     SP & Azithromycin    SP & Artesunate 
No  of  events     14/49   4/49     5/55   
Crude hazard ratio (95% CI)    1.00     0.23 (0.08-0.71)    0.25 (0.10-0.61) 
Adjusted hazard ratio (95% CI)†  1.00    0.19 (0.06-0.63)    0.25 (0.10-0.65) 
†Adjusted for baseline parasite density and gravidity 
Figure 3. The overall rate of recrudescence according to treatment group. The overall recrudescence rates comparing the three treatment groups
after adjusting for baseline parasite density and gravidity.
doi:10.1371/journal.pone.0001166.g003
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